Skip to Content

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

Data from the COAST-study was presented as Late-breaking at ESMO 2021. In this MEDtalk Roy S. Herbst, Medical Oncology, Yale Cancer Center, USA, gives his perspective of positive results for two new combination with durvalumab.

Roy S. Herbst

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top